Staiano A, Del Giudice E, Simeone D, Miele E, Marino A
Department of Pediatrics, University Federico II, Naples, Italy.
Dig Dis Sci. 1996 May;41(5):870-4. doi: 10.1007/BF02091525.
The efficacy of cisapride as a treatment for chronic constipation in children with severe brain damage was studied in 20 children. Each subject was randomly assigned to double-blind treatment with either cisapride (N = 10) or placebo (N = 10) for 12 weeks. Stool habits, total gastrointestinal transit time, colonic segmental transit times, and anorectal motility were evaluated in all children before and at the end of the treatment period. Although cisapride significantly (P < 0.05) increased stool frequency from baseline to week 12 and no significant change was documented in the placebo group, the mean change in stool frequency per week from baseline to 12 week was not significantly different between the two treatment groups. The use of laxatives or suppositories was significantly (P < 0.05) decreased by cisapride, but remained unchanged in the placebo group. Furthermore, cisapride significantly (P < 0.05) reduced rectal compliance but had no effect on total gastrointestinal transit time and colonic segmental transit times. In summary, in neurologically impaired children with chronic constipation, cisapride increased bowel frequency but did not alter the delay in total and segmental gastrointestinal transit times.
对20名患有严重脑损伤的儿童研究了西沙必利治疗慢性便秘的疗效。将每名受试者随机分配接受为期12周的西沙必利（N = 10）或安慰剂（N = 10）双盲治疗。在治疗期开始前及结束时对所有儿童的排便习惯、全胃肠通过时间、结肠节段通过时间和肛肠动力进行评估。虽然西沙必利使从基线至第12周的排便频率显著增加（P < 0.05），且安慰剂组未记录到显著变化，但两个治疗组从基线至12周每周排便频率的平均变化无显著差异。西沙必利使泻药或栓剂的使用显著减少（P < 0.05），但安慰剂组保持不变。此外，西沙必利显著降低了直肠顺应性（P < 0.05），但对全胃肠通过时间和结肠节段通过时间无影响。总之，在患有慢性便秘的神经功能受损儿童中，西沙必利增加了排便频率，但未改变全胃肠和节段性胃肠通过时间的延迟。
